Released exclusively at BIO-Europe this week in Munich, Germany, Medtrack's new unpartnered products report highlights private and public life science companies with the highest number of programs ripe for partnering opportunities.

In the private sector, the company with the most unpartnered programs is Aphios Corporation, which was also ranked at number one in the previous analysis by MedTrack. Aphios has 32 unpartnered products five in research stages, 25 preclinical assets, one Phase II and one Phase III opportunity. Making up the rest of the top five for private firms is Deciphera Pharmaceuticals LLC with 27 programs, Microbiotix Inc (26), Celprogen Inc (22), and Chikujee Therapeutics (21).

In big pharma, MedTrack has looked specifically at companies with unpartnered Phase III candidates in all therapeutic areas. This field includes,

• Novartis’ breast cancer drug BKM120 and acute myeloid leukemia therapy PKC412
• Bristol-Myer’s Squibb’s HIV drug BMS663068
• Amgen’s migraine product AMG334
• Novo Nordisk’s non-insulin-dependent diabetes therapy NN9535

For our disclosures, please read the BioMedTracker Research Standards.